Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients-Reference-Cited by-同舟云学术

Developing new drugs that activate the protective arm of the renin–angiotensin system as a potential treatment for respiratory failure in COVID-19 patients

Published:2021-05 Issue:5 Volume:26 Page:1311-1318
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Latil Mathilde,Camelo Serge,Veillet Stanislas,Lafont René,Dilda Pierre J.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference71 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin;Zhou;Nature,2020

2. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US;Gupta;JAMA Intern. Med.,2020

3. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19);Guo;JAMA Cardiol.,2020

4. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission;Xu;Sci. China Life Sci.,2020

5. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor;Hoffmann;Cell,2020

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancement in Beneficial Effects of AVE 0991: A Brief Review;Mini-Reviews in Medicinal Chemistry;2024-12

2. Emerging roles of the renin‐angiotensin system in select oral diseases;Oral Diseases;2024-09-09

3. Role of renin-angiotensin system/angiotensin converting enzyme-2 mechanism and enhanced COVID-19 susceptibility in type 2 diabetes mellitus;World Journal of Diabetes;2024-04-15

4. Review of COVID-19 Therapeutics by Mechanism: From Discovery to Approval;Journal of Korean Medical Science;2024

5. Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trial;eClinicalMedicine;2024-01